Local interstitial delivery of z-butylidenephthalide by polymer Wafers against malignant human gliomas

Neuro-Oncology

Volumn 13, Issue 6, 2011, Pages 635-648

  Harn, Horng Jyh ^a,b   Lin, Shinn Zong ^a,b   Lin, Po Cheng ^a,c   Liu, Cyong Yue ^d   Liu, Po Yen ^b   Chang, Li Fu ^d   Yen, Ssu Yin ^d   Hsieh, Dean Kuo ^e   Liu, Fu Chen ^d   Tai, Dar Fu ^d   Chiou, Tzyy Wen ^d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Gwo Xi Stem Cell Applied Technology   (Taiwan)

^d NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^e CHAOYANG UNIVERSITY OF TECHNOLOGY   (Taiwan)

Author keywords

Carmustine (BCNU); Glioblastoma multiforme (GBM); p(CPP SA) wafer; z butylidenephthalide (Bdph)

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; POLYMER; TRANSCRIPTION FACTOR; TRASCRIPTION FACTOR NURR 77; UNCLASSIFIED DRUG; ZETA BUTYLIDENEPHTHALIDE WAFER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; TUMOR MODEL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANGELICA SINENSIS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; KINETICS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PHTHALIC ANHYDRIDES; POLYMERS; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION;

EID: 79959929557     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor021     Document Type: Article

References (51)

1. Santarius T, Kirsch M, Rossi ML, Black PM. Molecular aspects of neuro-oncology. Clin Neurol Neurosur. 1997;99:184-195. (Pubitemid 27412441)
2. Cobb MA, Husain M, Andersen BJ, al-Mefty O. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J Neurosurg. 1996;84:85-90. (Pubitemid 26007001)
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21:1624-1636. (Pubitemid 46594118)
4. Blacklock JB, Wright DC, Dedrick RL, et al. Drug streaming during intra-arterial chemotherapy. J Neurosurg. 1986;64:284-291. (Pubitemid 16140344)
5. Shapiro WR, Green SB. Reevaluating the efficacy of intra-arterial BCNU. J Neurosurg. 1987;66:313-315.
6. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol. 1996;141:214-224. (Pubitemid 26338348)
7. Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Research 2001;61:7501-7506. (Pubitemid 32995040)
8. Nicholas MK, Prados MD, Larson D, Black PM, Loeffler J. Malignant astrocytomas in cancer of the nervous system. Oxford: Blackwell Publishers; 1997:464-491.
9. Boiardi A, Silvani A, Milanesi I, Botturi M, Broggi G. Primary glial tumor patients treated by combining cis-platin and etoposide. J Neurooncol. 1991;11:165-170.
10. Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol. 1992;10:1074-1077.
11. Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol. 1994;20:121-139. (Pubitemid 24309908)
12. White L, Sterling-Levis K, Fisher R, Tobias V. Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model. J Neurooncol. 1995;25:39-47.
13. Ma ZJ, Meng ZK, Zhang P. Chemical constituents from the radix of Curcuma wenyujin. Fitoterapia 2009;80:374-376.
14. Ko WC, Sheu JR, Tzeng SH, Chen CM. The selective antianginal effect without changing blood pressure of butylidenephthalide in conscious rats. Planta Med. 1998;64:229-232.
15. Ko WC, Liao CC, Shih CH, Lei CB, Chen CM. Relaxant effects of butylidenephthalide in isolated dog blood vessels. Planta Med. 2002;68:1004-1009. (Pubitemid 35448995)
16. Cheng YL, Chang WL, Lee SC, et al. Acetone extract of Angelica sinensis inhibits proliferation of human cancer cells via inducing cell cycle arrest and apoptosis. Life Sci. 2004;75:1579-1594.
17. Tsai NM, Lin SZ, Lee CC, et al. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res. 2005;11:3475-3484.
18. Tsai NM, Chen YL, Lee CC, et al. The natural compound nbutylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem. 2006;99:1251-1262.
19. Lin PC, Chen YL, Chiu SC, et al. Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J Neurochem. 2008;106:1017-1026.
20. Winoto A, Littman DR. Nuclear hormone receptors in T lymphocytes. Cell 2002;109 Suppl: S57-S66. (Pubitemid 34457852)
21. Williams GT, Lau LF. Activation of the inducible orphan receptor gene nur77 by serum growth factors: dissociation of immediate-early and delayed-early responses. Mol Cell Biol. 1993;13:6124-6136. (Pubitemid 23292607)
22. Woronicz JD, Calnan B, Ngo V, Winoto A. Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. Nature 1994;367:277-281. (Pubitemid 24051144)
23. Li H, Kolluri SK, Gu J, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000;289:1159-1164. (Pubitemid 30650723)
24. Li QX, Ke N, Sundaram R, Wong-Staal F. NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol Histopathol. 2006;21:533-540.
25. Kim H, Kim BY, Soh JW, Cho EJ, Liu JO, Youn HD. A novel function of Nur77: physical and functional association with protein kinase C. Biochem Biophys Res Commun. 2006;348:950-956. (Pubitemid 44233508)
26. 2+-induced release of the transcription factor MEF2. Science 1999;286:790-793.
27. Wilson AJ, Arango D, Mariadason JM, Heerdt BG, Augenlicht LH. TR3/Nur77 in colon cancer cell apoptosis. Cancer Res. 2003;63:5401-5407. (Pubitemid 37139857)
28. Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004;116:527-540. (Pubitemid 38264430)
29. Weih F, Ryseck RP, Chen L, Bravo R. Apoptosis of nur77/N10-transgenic thymocytes involves the Fas/Fas ligand pathway. Proc Natl Acad Sci U S A 1996;93:5533-5538. (Pubitemid 26159485)
30. Rajpal A, Cho YA, Yelent B, et al. Transcriptional activation of known and novel apoptotic pathways by Nur77 orphan steroid receptor. EMBO J 2003;22:6526-6536. (Pubitemid 38009600)
31. Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K, Safe S. Activation of Nur77 by selected 1, 1-Bis (3'-indolyl)-1-(p-substituted phenyl) methanes induces apoptosis through nuclear pathways. J Biol Chem. 2005;280:24903-24914. (Pubitemid 40934582)
32. Chen YL, Jian MH, Lin CC, et al. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol Pharmacol. 2008;74:1046-1058.
33. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Research 1993;53:329-333. (Pubitemid 23031845)
34. Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D. Morbidity and survival after 1, 3-bis (2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective casematched cohort series. Neurosurgery 1999;45:17-22, discussion 22-13.
35. McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO. Risk factors for postcraniotomy surgical site infection after 1, 3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis. 2003;36:759-765. (Pubitemid 36337980)
36. Domb AJ, Langer R. Polyanhydrides. I. Preparation of high molecular weight polyanhydrides. J Polym Sci. 1987;25:3373-3386. (Pubitemid 18533909)
37. Walter KA, Cahan MA, Gur A, et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Research 1994;54:2207-2212. (Pubitemid 24138696)
38. Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drugcarrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res. 1985;19:941-955. (Pubitemid 16257502)
39. Storm PB, Moriarity JL, Tyler B, Burger PC, Brem H, Weingart J. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J Neurooncol. 2002;56:209-217. (Pubitemid 34476989)
40. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 1995;62:605-609.
41. Janik P, Briand P, Hartmann NR. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Research 1975;35:3698-3704.
42. Chiu IM, Touhalisky K, Liu Y, Yates A, Frostholm A. Tumorigenesis in transgenic mice in which the SV40 T antigen is driven by the brainspecific FGF1 promoter. Oncogene 2000;19:6229-6239. (Pubitemid 32641836)
43. Ganguli-Indra G, Wasylyk C, Liang X, et al. CTIP2 expression in human head and neck squamous cell carcinoma is linked to poorly differentiated tumor status. PLoS One 2009;4:e5367.
44. Takaishi S, Tu S, Dubeykovskaya ZA, et al. Gastrin is an essential cofactor for helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice. Am J Pathol. 2009;175:365-375.
45. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
46. Le S, Zhu JJ, Anthony DC, Greider CW, Black PM. Telomerase activity in human gliomas. Neurosurgery 1998;42:1120-1124, discussion 1124-1125.
47. Counter CM, Meyerson M, Eaton EN, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998;16:1217-1222. (Pubitemid 28127521)
48. Ozawa T, Gryaznov SM, Hu LJ, et al. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol. 2004;6:218-226. (Pubitemid 39136505)
49. Lin PC, Chen YL, Chiu SC, et al. Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J Neurochem. 2008;106:1017-1026.
50. Chen YL, Jian MH, Lin CC, et al. The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma (HCC) cells therapy. Mol Pharmacol. 2008;74:1046-1058.
51. Sekiya K, Tezuka Y, Tanaka K, et al. Distribution, metabolism and excretion of butylidenephthalide of Ligustici chuanxiong rhizoma in hairless mouse after dermal application. J Ethnopharmacol. 2000;71:401-409. (Pubitemid 30642863)